AstraZeneca Opens First US Manipulated Cell Therapy Facility
AstraZeneca has invested $3.5 billion into American innovation, recently inaugurating its first US Manipulated Cell Therapy Manufacturing Facility in Maryland, aimed at assisting cancer patients.
The UK-based company stated that this new $300 million facility in Rockville showcases its belief in America’s position as a “global leader in science, manufacturing, and economic growth.”
“We recognize the significance of our work since lives and health are on the line,” remarked Pam Cheng, AstraZeneca’s executive vice president of global operations, during the facility’s grand opening. “I selected Maryland for this initiative because I trust in its tremendous talent, scientific expertise, and collaborative spirit.”
This facility will employ CAR-T cell therapy, a relatively recent approach for treating blood cancers like lymphoma and leukemia. For example, Andrew Gordon, a cancer survivor diagnosed with multiple myeloma back in 2013, underwent CAR-T cell therapy to fight the disease when it returned.
“This represents the cutting edge of cancer research,” Gordon expressed. “As patients, we are deeply appreciative of AstraZeneca’s commitment to this endeavor.”
The launch of this facility comes on the heels of AstraZeneca CEO Pascal Soriot’s remarks about the attractiveness of investing in the US healthcare sector versus other regions, particularly Europe. He highlighted that Europe currently allocates a significantly smaller percentage of GDP towards innovative medicines compared to the US.
President Donald Trump’s administration has promoted US innovation, with a recent surge in investment from various companies. AstraZeneca is looking to enhance its American manufacturing footprint; currently, its US operations contribute nearly 43% of its global revenue, with aspirations for that figure to reach 50% by 2030.
AstraZeneca’s overall $3.5 billion investment in US research and manufacturing encompasses various projects, including a Research and Development Center in Massachusetts and a specialized manufacturing facility in Texas.
“With 4,200 employees and over 9 billion doses produced annually within the US manufacturing network, we envision a future of advanced medicine that is truly homegrown,” noted the company in a statement.
